{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:24:30Z","timestamp":1755221070954,"version":"3.43.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":99,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.curtheres.2025.100793","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T19:12:36Z","timestamp":1744657956000},"page":"100793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-World Utilization Patterns, Safety, and Efficacy of Tafamidis in Patients With Hereditary Transthyretin Amyloidosis in Japan"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0751-530X","authenticated-orcid":false,"given":"Hiroaki","family":"Konishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Sekijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuharu","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2025.100793_bib0001","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s13023-023-02910-3","article-title":"Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal","volume":"18","author":"Ando","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.curtheres.2025.100793_bib0002","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.curtheres.2025.100793_bib0003","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.curtheres.2025.100793_bib0004","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13023-020-1340-x","article-title":"Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study","volume":"15","author":"In\u00eas","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.curtheres.2025.100793_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","article-title":"Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis","volume":"5","author":"Coelho","year":"2016","journal-title":"Neurol Ther"},{"key":"10.1016\/j.curtheres.2025.100793_bib0006","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.curtheres.2025.100793_bib0007","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.curtheres.2025.100793_bib0008","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","article-title":"Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years","volume":"24","author":"Barroso","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.curtheres.2025.100793_bib0009","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jns.2016.01.046","article-title":"Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: a phase III, open-label study","volume":"362","author":"Ando","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.curtheres.2025.100793_bib0010","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","article-title":"Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis","volume":"6","author":"Merlini","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.curtheres.2025.100793_bib0011","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13506129.2019.1643714","article-title":"A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy","volume":"26","author":"Huber","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.curtheres.2025.100793_bib0012","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000006543","article-title":"Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy","volume":"91","author":"Coelho","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.curtheres.2025.100793_bib0013","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00415-016-8064-9","article-title":"Monitoring effectiveness and safety of tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area","volume":"263","author":"Cortese","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.curtheres.2025.100793_bib0014","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40120-018-0097-9","article-title":"Positive effectiveness of tafamidis in delaying disease progression in transthyretin familial amyloid polyneuropathy up to 2 years: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"7","author":"Mundayat","year":"2018","journal-title":"Neurol Ther"},{"key":"10.1016\/j.curtheres.2025.100793_bib0015","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00415-016-8337-3","article-title":"Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study","volume":"264","author":"Plant\u00e9-Bordeneuve","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.curtheres.2025.100793_bib0016","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.clinthera.2020.07.001","article-title":"Characteristics of patients with hereditary transthyretin amyloidosis and an evaluation of the safety of tafamidis meglumine in Japan: an interim analysis of an all-case postmarketing surveillance","volume":"42","author":"Ishii","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.curtheres.2025.100793_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116424","article-title":"Development of measures of polyneuropathy impairment in hATTR amyloidosis: from NIS to mNIS\u202f+\u202f7","volume":"405","author":"Dyck","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.curtheres.2025.100793_bib0018","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/dia.2005.7.497","article-title":"The development and validation of the Norfolk QOL-DN, a new measure of patients\u2019 perception of the effects of diabetes and diabetic neuropathy","volume":"7","author":"Vinik","year":"2005","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.curtheres.2025.100793_bib0019","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.curtheres.2025.100793_bib0020","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mus.27668","article-title":"Factors associated with increased health-related quality-of-life benefits in hereditary transthyretin amyloidosis polyneuropathy patients treated with inotersen","volume":"66","author":"Karam","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.curtheres.2025.100793_bib0021","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2796.1994.tb01106.x","article-title":"Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy","volume":"235","author":"Suhr","year":"1994","journal-title":"J Intern Med"},{"key":"10.1016\/j.curtheres.2025.100793_bib0022","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/jamaoncol.2015.3113","article-title":"JAMA Oncology Patient Page. Performance status in patients with cancer","volume":"1","author":"West","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.curtheres.2025.100793_bib0023","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1253\/circj.CJ-20-0110","article-title":"JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis","volume":"84","author":"Kitaoka","year":"2020","journal-title":"Circ J"},{"key":"10.1016\/j.curtheres.2025.100793_bib0024","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2008.02.019","article-title":"Epidemiology of familial amyloid polyneuropathy in Japan: identification of a novel endemic focus","volume":"270","author":"Kato-Motozaki","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.curtheres.2025.100793_bib0025","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archneur.62.7.1057","article-title":"Transthyretin-related familial amyloidotic polyneuropathy","volume":"62","author":"Ando","year":"2005","journal-title":"Arch Neurol"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X25000189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X25000189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T08:43:30Z","timestamp":1754642610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X25000189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":25,"alternative-id":["S0011393X25000189"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2025.100793","relation":{},"ISSN":["0011-393X"],"issn-type":[{"type":"print","value":"0011-393X"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Utilization Patterns, Safety, and Efficacy of Tafamidis in Patients With Hereditary Transthyretin Amyloidosis in Japan","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2025.100793","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100793"}}